Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.
Mike BastianNick FreemantleAna Beatris RossiBrad ShumelGaelle Bego Le BagousseZhixiao WangYingxin XuPatricia GuyotPublished in: Dermatology and therapy (2024)